News tagged with avastin
Conversion of brain tumor cells into blood vessels thwarts treatment efforts
Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several ...
Jan 24, 2011 |
5 / 5 (7) |
1
|
Inexpensive drug to stop sight loss shown to be effective
An inexpensive, but unlicensed drug to help prevent severe sight loss in older people has been shown to be safe and effective, finds a study published in the British Medical Journal today.
Medicine & Health / Medications
Jun 10, 2010 |
4.3 / 5 (4) |
0
Cancer drug Avastin may cause kidney damage, study finds
A widely prescribed cancer drug noted for its ability to choke off blood vessels that help tumors grow can cause significant kidney damage in some patients, a team of Long Island scientists has found.
Medicine & Health / Medications
Jun 25, 2010 |
5 / 5 (3) |
1
$93,000 cancer drug: How much is a life worth?
Cancer patients, brace yourselves. Many new drug treatments cost nearly $100,000 a year, sparking fresh debate about how much a few months more of life is worth.
Sep 26, 2010 |
5 / 5 (3) |
6
Metastasis formation revealed in detail and real time
Up to 25% of cancer patients develop metastases in the brain - often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of ...
Dec 20, 2009 |
4.7 / 5 (3) |
0
A crystal ball for brain cancer? New method predicts which brain tumors will respond to drug
UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors ...
Jul 30, 2009 |
5 / 5 (2) |
0
World's first delivery of intra-arterial Avastin directly into brain tumor
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel ...
Nov 17, 2009 |
5 / 5 (2) |
0
Researchers optimistic in cancer fight, as disease spreads
Medical researchers are posting optimism in the long fight against cancer as advances were unveiled to combat the disease that continues to rise and remains the second biggest killer in the world.
Jun 08, 2010 |
5 / 5 (2) |
0
Kennedy's cancer puts focus on quality of life
(AP) -- He lived 15 months with an incurable brain tumor, a little longer than usual for a patient in his late 70s. Perhaps equally important is that Sen. Edward M. Kennedy lived those months well - able to work almost to ...
Aug 26, 2009 |
4.5 / 5 (2) |
0
Drug with unique disruption of tumor blood flow shows promise
Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).
Jan 13, 2010 |
5 / 5 (1) |
0
Hearing may be end of road for breast cancer drug
(AP) -- The best-selling cancer drug in the world comes under federal scrutiny once again this week, as drugmaker Roche makes a last-ditch effort to keep Avastin approved for breast cancer, despite evidence ...
Medicine & Health / Medications
Jun 27, 2011 |
5 / 5 (1) |
0
MicroRNA-based Diagnostic Identifies Squamous Lung Cancer with 96% Sensitivity
A new study shows for the first time that a microRNA-based diagnostic test can objectively identify squamous lung cancer with 96% sensitivity, according to Harvey Pass, M.D. of the NYU Cancer Institute at NYU Langone Medical ...
Mar 10, 2009 |
4 / 5 (1) |
0
Bevacizumab
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.
For more information about Bevacizumab, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
